Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED)

v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Operating expenses        
Research and development $ 346,217 $ 513,004 $ 1,574,357 $ 1,522,031
General and administrative 1,192,003 990,110 3,395,729 3,267,037
Total operating expenses 1,538,220 1,503,114 4,970,086 4,789,068
Operating loss (1,538,220) (1,503,114) (4,970,086) (4,789,068)
Other expense (income)        
Change in fair value of derivative liabilities (424,138) 3,126,464 (433,688) (2,024,660)
Fair value of derivative liabilities in excess of proceeds       322,644
Interest expense 182,614 301,547 520,594 711,575
Total other expense (income), net (241,524) 3,428,011 86,906 (990,441)
Loss before income taxes (1,296,696) (4,931,125) (5,056,992) (3,798,627)
Provision for income taxes     1,600 1,600
Net loss and comprehensive loss $ (1,296,696) $ (4,931,125) $ (5,058,592) $ (3,800,227)
Loss per common share:        
Basic (in dollars per share) $ (0.01) $ (0.04) $ (0.02) $ (0.03)
Diluted (in dollars per share) $ (0.01) $ (0.04) $ (0.03) $ (0.03)
Weighted average shares of common stock outstanding used to compute earnings per share:        
Basic (in shares) 256,758,472 133,001,746 207,536,173 132,885,675
Diluted (in shares) 257,255,653 133,001,746 208,434,966 167,690,989